Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apolipoprotein E and atherosclerosis: beyond lipid effect.

× No keyword cloud information.

35 in total

1. Apolipoprotein E genotyping and questionnaire-based assessment of lifestyle risk factors in dyslipidemic patients with a family history of Alzheimer's disease: test development for clinical application.

Authors: H K Lückhoff; M Kidd; S J van Rensburg; D P van Velden; M J Kotze
Journal: Metab Brain Dis Date: 2016-02 Impact factor: 3.584

Review 2. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors: C Roger White; David W Garber; G M Anantharamaiah
Journal: J Lipid Res Date: 2014-08-25 Impact factor: 5.922

3. The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.

Authors: Samantha Giordano-Mooga; Geeta Datta; Paul Wolkowicz; David W Garber; Mayakonda Palgunachari; C Roger White; G M Anantharamaiah
Journal: Curr Top Pept Protein Res Date: 2018

4. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium.

Authors: Nathalie Gaudreault; Nikit Kumar; Jessica M Posada; Kyle B Stephens; Nabora Soledad Reyes de Mochel; Delphine Eberlé; Victor R Olivas; Roy Y Kim; Matthew J Harms; Sean Johnson; Louis M Messina; Joseph H Rapp; Robert L Raffai
Journal: Arterioscler Thromb Vasc Biol Date: 2011-11-03 Impact factor: 8.311

5. Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis.

Authors: Kang Li; Daniel Ching; Fu Sang Luk; Robert L Raffai
Journal: Circ Res Date: 2015-04-22 Impact factor: 17.367

Review 6. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors: Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311

7. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors: Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal: Biochemistry Date: 2008-11-25 Impact factor: 3.162

8. VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation.

Authors: Sarada D Tetali; Madhu S Budamagunta; Catalina Simion; Laura J den Hartigh; Tamás Kálai; Kálmán Hideg; Danny M Hatters; Karl H Weisgraber; John C Voss; John C Rutledge
Journal: J Lipid Res Date: 2009-12-03 Impact factor: 5.922

9. Contributions of the carboxyl-terminal helical segment to the self-association and lipoprotein preferences of human apolipoprotein E3 and E4 isoforms.

Authors: Takaaki Sakamoto; Masafumi Tanaka; Charulatha Vedhachalam; Margaret Nickel; David Nguyen; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal: Biochemistry Date: 2008-01-18 Impact factor: 3.162

10. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.

Authors: Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah
Journal: Atherosclerosis Date: 2012-11-02 Impact factor: 5.162